Home > Research > Publications & Outputs > Population antibody responses following COVID-1...

Research

Links

Text available via DOI:

Keywords

View graph of relations

Population antibody responses following COVID-19 vaccination in 212,102 individuals

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Population antibody responses following COVID-19 vaccination in 212,102 individuals. / Ward, Helen; Whitaker, Matthew; Flower, Barnaby et al.
In: Nature Communications, Vol. 13, No. 1, 907, 16.02.2022.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Ward, H, Whitaker, M, Flower, B, Tang, SN, Atchison, C, Darzi, A, Donnelly, CA, Cann, A, Diggle, PJ, Ashby, D, Riley, S, Barclay, WS, Elliott, P & Cooke, GS 2022, 'Population antibody responses following COVID-19 vaccination in 212,102 individuals', Nature Communications, vol. 13, no. 1, 907. https://doi.org/10.1038/s41467-022-28527-x

APA

Ward, H., Whitaker, M., Flower, B., Tang, S. N., Atchison, C., Darzi, A., Donnelly, C. A., Cann, A., Diggle, P. J., Ashby, D., Riley, S., Barclay, W. S., Elliott, P., & Cooke, G. S. (2022). Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nature Communications, 13(1), Article 907. https://doi.org/10.1038/s41467-022-28527-x

Vancouver

Ward H, Whitaker M, Flower B, Tang SN, Atchison C, Darzi A et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nature Communications. 2022 Feb 16;13(1):907. doi: 10.1038/s41467-022-28527-x

Author

Ward, Helen ; Whitaker, Matthew ; Flower, Barnaby et al. / Population antibody responses following COVID-19 vaccination in 212,102 individuals. In: Nature Communications. 2022 ; Vol. 13, No. 1.

Bibtex

@article{956aa5124ea0436ba0b8e1bb98e9762b,
title = "Population antibody responses following COVID-19 vaccination in 212,102 individuals",
abstract = "Abstract: Population antibody surveillance helps track immune responses to COVID-19 vaccinations at scale, and identify host factors that may affect antibody production. We analyse data from 212,102 vaccinated individuals within the REACT-2 programme in England, which uses self-administered lateral flow antibody tests in sequential cross-sectional community samples; 71,923 (33.9%) received at least one dose of BNT162b2 vaccine and 139,067 (65.6%) received ChAdOx1. For both vaccines, antibody positivity peaks 4-5 weeks after first dose and then declines. At least 21 days after second dose of BNT162b2, close to 100% of respondents test positive, while for ChAdOx1, this is significantly reduced, particularly in the oldest age groups (72.7% [70.9–74.4] at ages 75 years and above). For both vaccines, antibody positivity decreases with age, and is higher in females and those with previous infection. Antibody positivity is lower in transplant recipients, obese individuals, smokers and those with specific comorbidities. These groups will benefit from additional vaccine doses.",
keywords = "Epidemiology, SARS-CoV-2, Viral infection",
author = "Helen Ward and Matthew Whitaker and Barnaby Flower and Tang, {Sonja N.} and Christina Atchison and Ara Darzi and Donnelly, {Christl A.} and Alexandra Cann and Diggle, {Peter J.} and Deborah Ashby and Steven Riley and Barclay, {Wendy S.} and Paul Elliott and Cooke, {Graham S.}",
year = "2022",
month = feb,
day = "16",
doi = "10.1038/s41467-022-28527-x",
language = "English",
volume = "13",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - Population antibody responses following COVID-19 vaccination in 212,102 individuals

AU - Ward, Helen

AU - Whitaker, Matthew

AU - Flower, Barnaby

AU - Tang, Sonja N.

AU - Atchison, Christina

AU - Darzi, Ara

AU - Donnelly, Christl A.

AU - Cann, Alexandra

AU - Diggle, Peter J.

AU - Ashby, Deborah

AU - Riley, Steven

AU - Barclay, Wendy S.

AU - Elliott, Paul

AU - Cooke, Graham S.

PY - 2022/2/16

Y1 - 2022/2/16

N2 - Abstract: Population antibody surveillance helps track immune responses to COVID-19 vaccinations at scale, and identify host factors that may affect antibody production. We analyse data from 212,102 vaccinated individuals within the REACT-2 programme in England, which uses self-administered lateral flow antibody tests in sequential cross-sectional community samples; 71,923 (33.9%) received at least one dose of BNT162b2 vaccine and 139,067 (65.6%) received ChAdOx1. For both vaccines, antibody positivity peaks 4-5 weeks after first dose and then declines. At least 21 days after second dose of BNT162b2, close to 100% of respondents test positive, while for ChAdOx1, this is significantly reduced, particularly in the oldest age groups (72.7% [70.9–74.4] at ages 75 years and above). For both vaccines, antibody positivity decreases with age, and is higher in females and those with previous infection. Antibody positivity is lower in transplant recipients, obese individuals, smokers and those with specific comorbidities. These groups will benefit from additional vaccine doses.

AB - Abstract: Population antibody surveillance helps track immune responses to COVID-19 vaccinations at scale, and identify host factors that may affect antibody production. We analyse data from 212,102 vaccinated individuals within the REACT-2 programme in England, which uses self-administered lateral flow antibody tests in sequential cross-sectional community samples; 71,923 (33.9%) received at least one dose of BNT162b2 vaccine and 139,067 (65.6%) received ChAdOx1. For both vaccines, antibody positivity peaks 4-5 weeks after first dose and then declines. At least 21 days after second dose of BNT162b2, close to 100% of respondents test positive, while for ChAdOx1, this is significantly reduced, particularly in the oldest age groups (72.7% [70.9–74.4] at ages 75 years and above). For both vaccines, antibody positivity decreases with age, and is higher in females and those with previous infection. Antibody positivity is lower in transplant recipients, obese individuals, smokers and those with specific comorbidities. These groups will benefit from additional vaccine doses.

KW - Epidemiology

KW - SARS-CoV-2

KW - Viral infection

U2 - 10.1038/s41467-022-28527-x

DO - 10.1038/s41467-022-28527-x

M3 - Journal article

VL - 13

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 907

ER -